Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia

The paper describes the outcomes from a clinical trial for Friedreich ataxia (the most common hereditary ataxia impacting walking, talking, heart and brain health). The trial did not show treatment efficacy.

Redenlab was the speech biomarker provider on the trial with Retrotope.

Click here to find out more.

Tags: , , , , ,

Related Post

Redenlab at the 39th Annual HDSA – May 30 – June 1

  • Posted on 30 May, 2024
    Join Redenlab at the upcoming Huntington’s Disease Society of America (HDSA) National Convention, starting on the 30th of May 2024...
    Read more

    Expanding the phenotype of Kleefstra syndrome: speech, language and cognition in 103 individuals

    • Posted on 31 March, 2024
      Speech and language impairments are core features of the neurodevelopmental genetic condition Kleefstra syndrome. The speech, language and cognitive profile...
      Read more

      Redenlab’s Chief Science Officer, Adam P. Vogel, PhD, leads groundbreaking study on speech analysis for neurodegenerative diseases

      • Posted on 25 January, 2024
        MEDIA RELEASE Melbourne, 19 January 2024 — Redenlab, a leader in innovative healthcare solutions, ispleased to announce a groundbreaking study...
        Read more